Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 233.82% from the stock’s previous close.

A number of other equities analysts have also weighed in on YMAB. Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Finally, Oppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Trading Down 6.8 %

Y-mAbs Therapeutics stock traded down $0.50 during mid-day trading on Friday, hitting $6.89. The company had a trading volume of 759,043 shares, compared to its average volume of 353,540. Y-mAbs Therapeutics has a 12 month low of $6.84 and a 12 month high of $20.90. The company has a market capitalization of $308.60 million, a PE ratio of -12.76 and a beta of 0.69. The stock’s 50 day moving average price is $10.47 and its two-hundred day moving average price is $12.16.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the firm earned ($0.18) EPS. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Caligan Partners LP boosted its position in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares during the period. State Street Corp boosted its holdings in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the period. Squarepoint Ops LLC increased its stake in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after buying an additional 74,452 shares in the last quarter. Millennium Management LLC increased its stake in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after buying an additional 67,233 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.